{"nctId":"NCT03724942","briefTitle":"Brexpiprazole for the Long-term Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type","startDateStruct":{"date":"2018-11-09","type":"ACTUAL"},"conditions":["Agitation Associated With Dementia of the Alzheimer's Type"],"count":164,"armGroups":[{"label":"Brexpiprazole","type":"EXPERIMENTAL","interventionNames":["Drug: Brexpiprazole"]}],"interventions":[{"name":"Brexpiprazole","otherNames":["OPC-34712"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients who completed the double-blind treatment period for 10 weeks and all observation, examination and evaluation at Week 10 of the double-blind trial.\n* Patients whose caregiver can properly collect the necessary information.\n\nExclusion Criteria:\n\n* Patients who had a serious adverse event which the principal investigator or sub-investigator assessed as related to the investigator product during the double-blind trial.\n* Patients who had delirium during the double-blind trial.","healthyVolunteers":false,"sex":"ALL","minimumAge":"55 Years","maximumAge":"89 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Frequency of Subjects With Treatment-Emergent Adverse Events (TEAEs)","description":"This trial enrolled subjects rolled over from Trial 331-102-00088, and the safety of brexpiprazole when administered for a maximum of 24 weeks (including the treatment period of Trial 331-102-00088) was evaluated.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.2","spread":null},{"groupId":"OG001","value":"90.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Cohen-Mansfield Agitation Inventory (CMAI) Score at 14 Weeks After Dosing","description":"The CMAI assessed the frequency of agitated behaviors in elderly persons, such as hitting, cursing, and restlessness. It consisted of 29 items all rated on a 1 to 7 scale with 1 being the \"best\" rating and 7 being the \"worst\" rating. The minimum possible CMAI total score was 29, and the maximum possible CMAI total score was 203. A decrease in score indicated improvement in symptoms.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","spread":"9.9"},{"groupId":"OG001","value":"-6.4","spread":"9.3"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Clinical Global Impression of Severity (CGI-S) Score at 14 Weeks After Dosing.","description":"The CGI-S was used to rate the severity of agitation. Scores were: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants. A decrease in score indicated improvement in symptoms.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"0.8"},{"groupId":"OG001","value":"-0.4","spread":"1.1"}]}]}]},{"type":"SECONDARY","title":"Clinical Global Impression of Improvement (CGI-I) Score at 14 Weeks After Dosing","description":"The CGI-I Scale was clinician-rated scale which assessed the total improvement of the patient's condition compared to that at baseline. Scores range from 0 to 7: 0 = Not assessed, 1= Very much improved, 2 = Much improved, 3= Minimally improved, 4= No change, 5= Minimally worse, 6= Much worse, 7= Very much worse. Higher scores indicate worse condition.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":"1.2"},{"groupId":"OG001","value":"2.7","spread":"1.1"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":102},"commonTop":["Somnolence","Insomnia","Fall","Sedation complication","Contusion"]}}}